Taken together, these investigations in humans reinforce the view that TREK-1 is a pivotal target of depression treatment, and the identification of selective blockers of TREK-1 may contribute to the emergence of a new generation of antidepressants. This evidence concerns the gene KCNK2 and depressive disorder.